Activated protein C (APC) is a serine protease with anticoagulant and cytoprotective activities. Nonanticoagulant APC mutants show beneficial effects as cytoprotective agents. To study, if such biased APC signaling can be achieved by APC-binding ligands, the aptamer technology has been used. A G-quadruplex-containing aptamer, G-NB3, has been selected that binds to the basic exosite of APC with a KD of 0.2 nM and shows no binding to APC-related serine proteases or the zymogen protein C. G-NB3 inhibits the inactivation of activated cofactors V and VIII with IC50 values of 11.6 and 13.1 nM, respectively, without inhibiting the cytoprotective and anti-inflammatory functions of APC as tested using a staurosporine-induced apoptosis assay and a vascular barrier protection assay. In addition, G-NB3 prolongs the plasma half-life of APC through inhibition of APC-serine protease inhibitor complex formation. These physicochemical and functional characteristics qualify G-NB3 as a promising therapeutic agent usable to enhance the cytoprotective functions of APC without increasing the risk of APC-related hemorrhage.
Get full access to this article
View all access options for this article.
References
1.
Esmon CT. (2003). The protein C pathway. Chest 124 (3 Suppl.):26S–32S.
2.
DahlbackB. (2005). Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases. J Intern Med, 257:209–223.
3.
ShahzadK, KohliS, Al-DabetMM and IsermannB. (2019). Cell biology of activated protein C. Curr Opin Hematol, 26:41–50.
4.
RiewaldM, PetrovanRJ, DonnerA, MuellerBM and RufW. (2002). Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science, 296:1880–1882.
5.
Nieman MT. (2016). Protease-activated receptors in hemostasis. Blood, 128:169–177.
6.
IsermannB. (2017). Homeostatic effects of coagulation protease-dependent signaling and protease activated receptors. J Thromb Haemost, 15:1273–1284.
7.
DahlbackB and VilloutreixBO. (2005). Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition. Arterioscler Thromb Vasc Biol, 25:1311–1320.
8.
YangL, ManithodyC and RezaieAR. (2002). Contribution of basic residues of the 70-80-loop to heparin binding and anticoagulant function of activated protein C. Biochemistry, 41:6149–6157.
9.
YangL, BaeJ-S, ManithodyC and RezaieAR. (2007). Identification of a specific exosite on activated protein C for interaction with protease-activated receptor 1. J Biol Chem, 282:25493–25500.
10.
GriffinJH, ZlokovicBV and MosnierLO. (2015). Activated protein C: biased for translation. Blood, 125:2898–2907.
11.
MosnierLO, YangXV and GriffinJH. (2007). Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. J Biol Chem, 282:33022–33033.
12.
BaeJ-S, YangL, ManithodyC and RezaieAR. (2007). Engineering a disulfide bond to stabilize the calcium-binding loop of activated protein C eliminates its anticoagulant but not its protective signaling properties. J Biol Chem, 282:9251–9259.
13.
HarmonS, PrestonRJ, Ni AinleF, JohnsonJA, CunninghamMS, SmithOP, WhiteB and O'DonnellJS. (2008). Dissociation of activated protein C functions by elimination of protein S cofactor enhancement. J Biol Chem, 283:30531–30539.
14.
BergDT, GerlitzB, ShangJ, SmithT, SantaP, RichardsonMA, KurzKD, GrinnellBW, MaceK and JonesBE. (2003). Engineering the proteolytic specificity of activated protein C improves its pharmacological properties. Proc Natl Acad Sci U S A, 100:4423–4428.
15.
GriffinJH, ZlokovicBV and MosnierLO. (2018). Activated protein C, protease activated receptor 1, and neuroprotection. Blood, 132:159–169.
16.
LydenP, PryorKE, CoffeyCS, CudkowiczM, ConwitR, JadhavA, SawyerRNJr., ClaassenJ, AdeoyeO, et al. (2019). Final results of the RHAPSODY trial: a multi-center, phase 2 trial using a continual reassessment method to determine the safety and tolerability of 3K3A-APC, a recombinant variant of human activated protein C, in combination with tissue plasminogen activator, mechanical thrombectomy or both in moderate to severe acute ischemic stroke. Ann Neurol, 85:125–136.
17.
SperandioO, WildhagenKC, SchrijverR, WieldersS, VilloutreixBO and NicolaesGA. (2014). Identification of novel small molecule inhibitors of activated protein C. Thromb Res, 133:1105–1114.
18.
DahlbackB. (2014). Targeting exosites of activated protein C as therapeutic possibility? Thromb Res, 133:963–964.
19.
Sullenger BA. (2016). Aptamers coming of age at twenty-five. Nucleic Acid Ther, 26:119.
20.
MayerG. (2009). The chemical biology of aptamers. Angew Chem Int Ed Engl, 48:2672–2689.
21.
NimjeeSM, WhiteRR, BeckerRC and SullengerBA. (2017). Aptamers as Therapeutics. Annu Rev Pharmacol Toxicol, 57:61–79.
22.
MüllerJ, IsermannB, DückerC, SalehiM, MeyerM, FriedrichM, MadhusudhanT, OldenburgJ, MayerG and PötzschB. (2009). An exosite-specific ssDNA aptamer inhibits the anticoagulant functions of activated protein C and enhances inhibition by protein C inhibitor. Chem Biol, 16:442–451.
23.
HamedaniNS and MüllerJ. (2016). Capillary electrophoresis for the selection of DNA aptamers recognizing activated protein C. Methods Mol Biol, 1380:61–75.
24.
HamedaniNS, BlümkeF, TolleF, RohrbachF, RühlH, OldenburgJ, MayerG, PötzschB and MüllerJ. (2015). Capture and release (CaR): a simplified procedure for one-tube isolation and concentration of single-stranded DNA during SELEX. Chem Commun (Camb), 51:1135–1138.
25.
TolleF and MayerG. (2016). Preparation of SELEX samples for next-generation sequencing. Methods Mol Biol, 1380:77–84.
26.
ZukerM. (2003). Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res, 31:3406–3415.
27.
KikinO, D'AntonioL and BaggaPS. (2006). QGRS Mapper: a web-based server for predicting G-quadruplexes in nucleotide sequences. Nucleic Acids Res, 34:W676–W682.
28.
HemkerHC, GiesenP, Al DieriR, RegnaultV, de SmedtE, WagenvoordR, LecompteT and BéguinS. (2003). Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb, 33:4–15.
29.
RussoA, SohUJ, PaingMM, AroraP and TrejoJ. (2009). Caveolae are required for protease-selective signaling by protease-activated receptor-1. Proc Natl Acad Sci U S A, 106:6393–6397.
30.
FriedrichU, NicolaesGA, VilloutreixBO and DahlbackB. (2001). Secondary substrate-binding exosite in the serine protease domain of activated protein C important for cleavage at Arg-506 but not at Arg-306 in factor Va. J Biol Chem, 276:23105–23108.
31.
BockLC, GriffinLC, LathamJA, VermaasEH and TooleJJ. (1992). Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature, 355:564–566.
32.
TassetDM, KubikMF and SteinerW. (1997). Oligonucleotide inhibitors of human thrombin that bind distinct epitopes. J Mol Biol, 272:688–698.
33.
MüllerJ, WulffenB, PotzschB and MayerG. (2007). Multidomain targeting generates a high-affinity thrombin-inhibiting bivalent aptamer. Chembiochem, 8:2223–2226.
34.
KimY, CaoZ and TanW. (2008). Molecular assembly for high-performance bivalent nucleic acid inhibitor. Proc Natl Acad Sci U S A, 105:5664–5669.
35.
PlatellaC, RiccardiC, MontesarchioD, RovielloGN and MusumeciD. (2017). G-quadruplex-based aptamers against protein targets in therapy and diagnostics. Biochim Biophys Acta Gen Subj, 1861:1429–1447.
36.
ShigdarS, MacdonaldJ, O'ConnorM, WangT, XiangD, Al ShamailehH, QiaoL, WeiM, ZhouSF, et al. (2013). Aptamers as theranostic agents: modifications, serum stability and functionalisation. Sensors (Basel), 13:13624–13637.
37.
ShawJP, KentK, BirdJ, FishbackJ and FroehlerB. (1991). Modified deoxyoligonucleotides stable to exonuclease degradation in serum. Nucleic Acids Res, 19:747–750.
38.
DupontDM, ThuesenCK, BøtkjaerKA, BehrensMA, DamK, SørensenHP, PedersenJS, PlougM, JensenJK and Andreasen.PA (2015). Protein-binding RNA aptamers affect molecular interactions distantly from their binding sites. PLoS One, 10:e0119207.
39.
TanX, DeySK, TelmerC, ZhangX, ArmitageBA and BruchezMP. (2014). Aptamers act as activators for the thrombin mediated-hydrolysis of peptide substrates. Chembiochem, 15:205–208.
40.
PetreraNS, StaffordAR, LeslieBA, KretzCA, FredenburghJC and WeitzJI. (2009). Long range communication between exosites 1 and 2 modulates thrombin function. J Biol Chem, 284:25620–25629.
41.
GlasscockLN, GerlitzB, CooperST, GrinnellBW and ChurchFC. (2003). Basic residues in the 37-loop of activated protein C modulate inhibition by protein C inhibitor but not by alpha(1)-antitrypsin. Biochim Biophys Acta, 1649:106–117.
42.
MartosL, RamónLA, OtoJ, Á Fernández-Pardo, BonanadS, CidAR, GruberA, GriffinJH, EspañaF, NavarroS and MedinaP. (2018). Alpha2-macroglobulin is a significant in vivo inhibitor of activated protein C and low APC:alpha2M levels are associated with venous thromboembolism. Thromb Haemost, 118:630–638.
43.
Marti-CarvajalAJ, SolaI, GluudC, LathyrisD and Cardona.AF (2012). Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients. Cochrane Database Syst Rev, 12:CD004388.
44.
BecherT, MüllerJ, AkinI, BaumannS, BoschK, StachK, BorggrefeM, PötzschB and LoßnitzerD. (2018). The evolution of activated protein C plasma levels in septic shock and its association with mortality: a prospective observational study. J Crit Care, 47:41–48.
45.
BalversK, WirtzMR, van DierenS, GoslingsJC and Juffermans.NP (2015). Risk factors for trauma-induced coagulopathy- and transfusion-associated multiple organ failure in severely injured trauma patients. Front Med (Lausanne), 2:24.
46.
HamedaniNS, RühlH, ZimmermannJJ, HeiselerT, OldenburgJ, MayerG, PötzschB and MüllerJ. (2016). In vitro evaluation of aptamer-based reversible inhibition of anticoagulant activated protein C as a novel supportive hemostatic approach. Nucleic Acid Ther, 26:355–362.
47.
PolderdijkSG, AdamsTE, IvanciuL, CamireRM, BaglinTP and HuntingtonJA. (2017). Design and characterization of an APC-specific serpin for the treatment of hemophilia. Blood, 129:105–113.
48.
RusconiCP, RobertsJD, PitocGA, NimjeeSM, WhiteRR, QuickGJr., ScardinoE, FayWP and SullengerBA. (2004). Antidote-mediated control of an anticoagulant aptamer in vivo. Nat Biotechnol, 22:1423–1428.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
